Richard Hubner
Overview
Explore the profile of Richard Hubner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu J, Kato K, Hubner R, Park S, Kojima T, Ishihara R, et al.
Adv Ther
. 2025 Mar;
PMID: 40075024
Introduction: The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against the use of programmed cell death protein-1 inhibitors for first-line treatment of advanced or...
2.
Robinson M, Wheatley R, Foster L, Jamdar S, Siriwardena A, Lamarca A, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300572.
PMID: 38662981
No abstract available.
3.
Suddle A, Reeves H, Hubner R, Marshall A, Rowe I, Tiniakos D, et al.
Gut
. 2024 Apr;
73(8):1235-1268.
PMID: 38627031
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC...
4.
McNamara M, Bridgewater J, Goyal L, Jacobs T, Wagner A, Goldstein D, et al.
BMJ Open
. 2022 Oct;
12(10):e064954.
PMID: 36288834
Objectives: Female physicians in medicine are increasing, but disparities in female authorship exist. The aim of this study was to characterise factors associated with female first (FF) and female senior...
5.
Exarchou K, Hu H, Stephens N, Moore A, Kelly M, Lamarca A, et al.
Endocrine
. 2022 Jul;
78(1):186-196.
PMID: 35895180
Purpose: Type I gastric neuroendocrine neoplasms (g-NENs) have a low risk of metastasis and a generally favourable prognosis. Patients with small type I g-NENs (≤10 mm) frequently require no treatment,...
6.
Kapacee Z, Allison J, Dawod M, Wang X, Frizziero M, Chakrabarty B, et al.
Curr Oncol
. 2022 Jul;
29(7):5110-5125.
PMID: 35877265
Background: Brain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP-NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features,...
7.
Cuthbertson D, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, et al.
Front Endocrinol (Lausanne)
. 2021 Jun;
12:654975.
PMID: 34163434
Objective: Pancreatic neuroendocrine tumours (panNETs) arise sporadically or as part of a genetic predisposition syndrome. CT/MRI, endoscopic ultrasonography and functional imaging using Octreoscan localise and stage disease. This study aimed...
8.
Malik A, Lamarca A, Siriwardena A, OReilly D, Deshpande R, Satyadas T, et al.
Pancreas
. 2020 Feb;
49(2):201-207.
PMID: 32011535
Objective: The aim of the study was to determine the impact of age on curative management and outcomes of patients with pancreatic ductal adenocarcinoma. Methods: Patients who underwent resection for...
9.
Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K, et al.
Lancet Gastroenterol Hepatol
. 2019 Sep;
4(11):854-862.
PMID: 31477558
Background: Preclinical, epidemiological, and randomised data indicate that aspirin might prevent tumour development and metastasis, leading to reduced cancer mortality, particularly for gastro-oesophageal and colorectal cancer. Randomised trials evaluating aspirin...
10.
Lewis A, Wang X, Magdalani L, DArienzo P, Bashir C, Mansoor W, et al.
World J Gastroenterol
. 2018 Feb;
24(6):671-679.
PMID: 29456406
Aim: To compare health-related quality of life (HRQoL), anxiety, depression, and impulsivity scores in patients with and without carcinoid syndrome (CS), and correlated them with serum 5-hydroxyindoleacetic acid (5-HIAA) levels....